Stock Market | FinancialContent Business Page
Nexcella, Inc., a subsidiary of Immix Biopharma, completed a Pre-IND meeting with the FDA for NXC-201, targeting AL amyloidosis and multiple myeloma. The meeting discussed US manufacturing and clinical trials, aiming for regulatory clarity to proceed with an IND application. NXC-201, a BCMA-targeted CAR-T cell therapy, has shown promising response rates in ongoing trials.
Related Clinical Trials
Reference News
Stock Market | FinancialContent Business Page
Nexcella, Inc., a subsidiary of Immix Biopharma, completed a Pre-IND meeting with the FDA for NXC-201, targeting AL amyloidosis and multiple myeloma. The meeting discussed US manufacturing and clinical trials, aiming for regulatory clarity to proceed with an IND application. NXC-201, a BCMA-targeted CAR-T cell therapy, has shown promising response rates in ongoing trials.